Europe Pharmaceutical Contract Manufacturing Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Europe's pharmaceutical contract manufacturing sector covers a broad spectrum of services including active pharmaceutical ingredient (API) production, finished dosage form manufacturing, sterile and non-sterile processing, clinical trial supply, and secondary packaging. The market serves multinational pharmaceutical companies, mid-sized drug developers, and biotechnology firms that rely on external manufacturing capacity for both commercial products and investigational therapies.

• •The market is valued at approximately $46.0 billion in 2025 and is expanding at a compound annual growth rate of around 6.5 percent.
• •The sector spans traditional CMO arrangements as well as integrated CDMO services that combine drug development with manufacturing from clinical through commercial stages.
• •Longer-term projections suggest the broader market could reach between $94 billion and $108 billion by 2035, supported by biologic growth and new manufacturing technologies.

Pharmaceutical companies increasingly outsource manufacturing to optimize capital allocation, access specialized technical capabilities, and reduce development timelines without building expensive internal infrastructure. The biologics revolution, encompassing monoclonal antibodies, vaccines, and cell-based therapies, requires sophisticated manufacturing platforms and expertise that many smaller and even mid-sized drug developers cannot economically maintain in-house. Europe's rigorous regulatory standards also encourage outsourcing to established contract partners with demonstrated compliance and quality management systems.

• •The biopharmaceutical contract manufacturing segment alone is projected to reach approximately $27.7 billion by 2031, reflecting a compound annual growth rate of roughly 13.6 percent.
• •Growing complexity of drug pipelines, including advanced therapies such as cell and gene treatments, drives demand for specialized manufacturing expertise and facilities.
• •Cost containment pressures, combined with the need for flexible manufacturing capacity amid generic drug growth and patent expirations, continue expanding outsourcing relationships.

The market is segmented by service type into commercial manufacturing, development services, and specialized offerings including sterile injectables, oral solid dosage, and biologic production. Regional activity remains centered in Western Europe, where Germany, Switzerland, France, Italy, and the United Kingdom hold the largest concentration of contract manufacturing capacity. Ireland and several Eastern European nations have also gained prominence due to favorable operating conditions, regulatory alignment, and ongoing infrastructure investment.

• •Biologic and sterile contract manufacturing represents one of the fastest-growing subsegments, reflecting the industry-wide shift toward large-molecule and complex drug products.
• •Western Europe accounts for the majority of market share, with Ireland, Poland, and the Czech Republic attracting growing investment from global contract manufacturers.
• •Service coverage ranges from early-stage API development and formulation work through to large-scale commercial production and global packaging logistics.

What are the recent trends and outlook?

The market outlook remains constructive as biologic drug growth, personalized medicine, and advanced therapies such as cell and gene treatments continue reshaping pharmaceutical manufacturing requirements. CDMO relationships are evolving toward deeper strategic partnerships, with sponsors seeking integrated providers capable of supporting molecules from early development through full commercial launch and lifecycle management. Continued investment in biologic capacity, particularly for monoclonal antibodies and viral vector manufacturing, is anticipated across the sector.

• •Analysts project sustained double-digit growth for biologic-focused contract manufacturing, while the broader market is expected to continue expanding at a mid-single-digit pace.
• •Advances in continuous manufacturing and single-use processing technologies are improving manufacturing flexibility and reducing production timelines.
• •Supply chain resilience and regionalization trends may influence future facility investment and capacity allocation decisions among European contract manufacturers.